Setting 
My Cart

Ordered before 17:30, shipped today - Support: (012) 800 456 789

Track Your Order

Toggle Nav
mobile icon
Close
  • Menu
  • Setting
  • Home
  • Search results for: 'research area jak stat signaling egfr'

Search results for: 'research area jak stat signaling egfr'

8 Items

per page
  1. Gefitinib (ZD1839)
    A8219 Gefitinib (ZD1839)
     3 Citation
    Target: EGFR
    Summary: Selective EGFR inhibitor
      ≥22.34 mg/mL
  2. Ruxolitinib (INCB018424)
    A3012 Ruxolitinib (INCB018424)
     4 Citation
    Target: JAK
    Summary: JAK inhibitor
      insoluble in H2O; ≥15.32 mg/mL
  3. Trametinib (GSK1120212)
    A3018 Trametinib (GSK1120212)
     7 Citation
    Target: MEK
    Summary: MEK1 and MEK2 inhibitor, potent and selective
      insoluble in H2O; insoluble in EtOH; ≥15.38 mg/mL
  4. Gefitinib hydrochloride
    A3433 Gefitinib hydrochloride
    Target: EGFR
    Summary: Potent EGFR inhibitor
      insoluble in EtOH; ≥4.28 mg/mL
  5. BYL-719
    A8346 BYL-719
     1 Citation
    Target: PI3K
    Summary: Selective PI3Kα inhibitor
      ≥22.07 mg/mL
  6. Everolimus (RAD001)
    A8169 Everolimus (RAD001)
     8 Citation
    Target: mTOR
    Summary: MTOR inhibitor
      ≥47.91 mg/mL
  7. LY2090314
    A3570 LY2090314
    Target: GSK-3
    Summary: Potent GSK-3 inhibitor
      insoluble in H2O; ≥91 mg/mL
  8. Tivantinib (ARQ 197)
    A8325 Tivantinib (ARQ 197)
     2 Citation
    Target: MET
    Summary: C-Met inhibitor,non-ATP-competitive
      ≥18.47 mg/mL

8 Items

per page